Zevra Therapeutics (ZVRA) Gains from Investment Securities (2014 - 2023)
Zevra Therapeutics (ZVRA) posted Gains from Investment Securities of $2000.0 for Q1 2023, up 106.06% on a QoQ basis from -$33000.0 in Q4 2022, and up 100.83% year-over-year from $995.87 in Q1 2022.
Zevra Therapeutics (ZVRA) Gains from Investment Securities (2014 - 2023) Analysis & Trends
Zevra Therapeutics' Gains from Investment Securities history runs 10 years deep, the most recent figure standing at $2000.0 for Q1 2023.
- Quarterly Gains from Investment Securities rose 100.83% year-over-year to $2000.0 in Q1 2023, while the trailing twelve-month figure through Sep 2023 was -$31000.0 (up 91.41% YoY) and the FY2022 annual result came in at -$328000.0, down 1361.54% from the prior year.
- Gains from Investment Securities was $2000.0 for Q1 2023 at Zevra Therapeutics, up from -$33000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $394000.0 in Q2 2021 and bottomed at -$1.4 million in Q3 2019.
- A 5-year average of -$124352.9 and a median of -$32000.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2021 — Gains from Investment Securities jumped 13033.33% — and 2022, when it plunged 903.33%.
- Zevra Therapeutics' Gains from Investment Securities stood at -$215000.0 in 2019, then soared by 155.35% to $119000.0 in 2020, then slumped by 155.46% to -$66000.0 in 2021, then soared by 50.0% to -$33000.0 in 2022, then surged by 106.06% to $2000.0 in 2023.
- Business Quant data shows ZVRA's Gains from Investment Securities at $2000.0 in Q1 2023, -$33000.0 in Q4 2022, and -$22000.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Zevra Therapeutics | 570.04 Mn | 369.43 Mn | 34.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 2,000.00 |
| Mar 31, 2023 | 2,000.00 |
| Dec 31, 2022 | -33,000.00 |
| Dec 31, 2022 | -33,000.00 |
| Sep 30, 2022 | -22,000.00 |
| Sep 30, 2022 | -22,000.00 |
| Jun 30, 2022 | -32,000.00 |
| Jun 30, 2022 | -32,000.00 |
| Mar 31, 2022 | -241,000.00 |
| Mar 31, 2022 | -241,000.00 |
| Dec 31, 2021 | -66,000.00 |
| Dec 31, 2021 | -66,000.00 |
| Sep 30, 2021 | -332,000.00 |
| Sep 30, 2021 | -332,000.00 |
| Jun 30, 2021 | 394,000.00 |
| Jun 30, 2021 | 394,000.00 |
| Mar 31, 2021 | 30,000.00 |
| Mar 31, 2021 | 30,000.00 |
| Dec 31, 2020 | 119,000.00 |
| Dec 31, 2020 | 119,000.00 |